Biotechnology

AKESO

JPMorgan Maintains Positive Rating on CanAngela Biopharma

Chinese Innovative Pharmaceutical Companies Excel at 2026 ASCO Conference, Boosting Global Influence

First Shanghai Securities and CMB International Securities Maintain Buy Rating for Akeso

CanSino Biologics' AK112 Beats Merck's Keytruda, Achieves Systemic Transformation in Two Years

Guo Jin Securities Predicts Kangke Biotech's 2026 Net Profit to Grow Significantly

CICC and China International Securities Maintain Buy Rating and Set Target Price for Kangao Biologics

Canbiopharm Revenue Increases 43.9% in 2025, IVO-3001 FDA Application Accepted

CanAngen's Revenue Grew by 43.9% to 3.056 Billion Yuan in 2025

AKESO released FY2025 Q3 earnings on March 26, 2026 (BJT) with actual revenue of HKD 898.99 M and EPS of HKD -0.3259

AKESO released FY2025 9-month earnings on March 26 (BJT), actual revenue HKD 2.427 B, actual EPS HKD -1.0188

Kangkang Biotech Inc. Revenue Reaches 3.056 Billion Yuan in 2025, Loss Widens to 1.141 Billion Yuan

AKESO released FY2025 earnings on March 26 During-Market (BJT), actual revenue HKD 3.34 B (forecast HKD 3.655 B), actual EPS HKD -1.3473 (forecast HKD -0.3407)

AKESO released FY2025 Q4 earnings on March 26 During-Market (BJT), actual revenue HKD 914.5 M, actual EPS HKD -0.3315

AKESO to release FY2025 earnings report on March 26 During-Market (BJT), forecast revenue HKD 3.726 B, EPS HKD -0.3479

CanAngen's AK150 Receives Clinical Trial Approval

Nomura Adjusts Kanghong Biotech Revenue Forecast and Target Price

CanSino and Inovio Partner to Evaluate Efficacy in Glioblastoma Treatment

NMPA Approves Kangkang Biotech's AK139 to Enter Phase II Clinical Trials for 7 Indications

Kangkang Biologics Grants JinChuan Pharmaceutical Exclusive Commercialization Rights to Enoximab

CanSino Biologics' PD-1/VEGF Bi-specific Antibody Ivolimab Receives FDA Acceptance

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02513

02476

03986

06869

06613

02015

01209

09926

00175

01109

KNOWLEDGE ATLAS(02513) rose 9.33%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 878.5%. VGT(02476) rose 8.47%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 75.7%. LI AUTO-W(02015) fell 14.15%, with a trading turnover 3.6 Billion HKD, and a year-to-date rose 0.1%. CHINA RES MIXC(01209) fell 6.19%, with a trading turnover 346.3 Million HKD, and a year-to-date rose 6.7%.

- The Hang Seng Index decreased by 1.11%, with a year-to-date increase of 0.2%.  
- The Hang Seng Tech Index fell by 1.95%, reflecting a year-to-date decline of 12.2%.  
- Notable stock movements include Zhizhu's 9.33% increase and an 878.5% cumulative rise for the year, alongside Lixiang Auto's 14.15% drop with minimal year-to-date growth.

Top Gainers&Losers

KNOWLEDGE ATLAS

GIGADEVICE

YOFC

Lens

LI AUTO-W

CHINA RES MIXC

GEELY AUTO

CHINA RES LAND

Top 5 HK Stock Gainers/Losers (>100B) (5.18)

01681

06160

CONSUN PHARMA has recently shown a steady upward trend, with an increase of approximately 12.27%. The MACD daily bullish signal is gradually being established, with the fast and slow lines crossing above the zero axis, which usually indicates that the medium-term trend is transitioning from a consolidation phase to an upward breakout. The trading volume is about HKD 72.39 million, which, although not a large absolute amount, has significantly increased compared to the stock's historical average daily volume, indicating a rise in capital participation. The stock price is steadily rising, and the short-term moving averages are beginning to turn upward, forming an initial bullish arrangement. On the news front, the overall recovery trend in the pharmaceutical sector is evident. The Hong Kong stock biopharmaceutical index has stabilized and rebounded, with AKESO rising over 4% on the day and BEONE MEDICINES increasing nearly 3%, showing clear signs of capital returning to the sector. As a leader in the traditional Chinese medicine nephrology field, CONSUN PHARMA has a stable product matrix and excellent cash flow performance, making it a defensive yet flexible choice in the rotation of the pharmaceutical sector. Additionally, the domestic medical insurance policy's supportive stance towards traditional Chinese medicine remains unchanged, and the impact of centralized procurement on exclusive varieties is limited. The company's fundamentals are relatively certain, attracting some funds seeking stable returns. From a technical perspective, the current stock price is operating above the 5-day and 10-day moving averages, with both moving averages trending upward and maintaining a moderate distance, forming a step-like support. If today's trading volume remains above HKD 70 million and holds above the 5-day moving average, the upward trend is expected to continue. Attention should be paid to the previous high-pressure zone above, as a breakthrough may open up new upward space. The correlation between the Hong Kong pharmaceutical sector and the A-share market is worth noting, as the A-share market has also been active in the innovative drug sector recently

Technical Forecast

CONSUN PHARMA

BEONE MEDICINES

Pre-market trend | CONSUN PHARMA (1681.HK) 5/6 moderately increased with volume, is capital flowing back into the pharmaceutical sector?

09903

00100

02338

00027

00857

06656

00883

ILUVATAR COREX(09903) rose 20.22%, with a trading turnover 1.2 Billion HKD, and a year-to-date rose 287.3%. MINIMAX-W(00100) rose 12.62%, with a trading turnover 1.4 Billion HKD, and a year-to-date rose 386.7%. AKESO(09926) fell 5.89%, with a trading turnover 924.7 Million HKD, and a year-to-date rose 13.1%. GALAXY ENT(00027) fell 2.83%, with a trading turnover 688.9 Million HKD, and a year-to-date fell 15.9%.

ILUVATAR COREX

MINIMAX-W

WEICHAI POWER

GALAXY ENT

PETROCHINA

SIGENERGY

CNOOC

Top 5 HK Stock Gainers/Losers (>100B) (5.4)

02427

00839

00470

02402

01440

02623

00107

00576

02232

GUANZE MEDICAL(02427) fell 11.96%, with a trading turnover 48.2 Million HKD, and a year-to-date rose 1164.2%. CHINA EDU GROUP(00839) fell 9.48%, with a trading turnover 25.2 Million HKD, and a year-to-date fell 32.3%. WUXI LEAD(00470) fell 8.67%, with a trading turnover 109.8 Million HKD, and a year-to-date rose 18.4%.

GUANZE MEDICAL

CHINA EDU GROUP

WUXI LEAD

SINOHYTEC

STAR SHINE HLDG

ADD NEW ENERGY

SICHUAN EXPRESS

ZHEJIANGEXPRESS

CRYSTAL INTL

Top 10 HK Stock Losers (5.4)

On April 28, 2026, in Hong Kong, Akeso, Inc.revealed that ivonescimab, their groundbreaking PD-1/VEGF bispecific antibody, has obtained significant enhancements and advancements in various treatment settings. The company's innovative drug has received widespread recognition and improvements for both initial and subsequent treatment stages.

Unusual Whales

Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline

520690

516930

159506

516500

BofAS reported that Akeso's cadonilimab achieved month-over-month growth despite seasonal trends. In February, Akeso's drug sales reached RMB71.3 million, a 319.6% year-over-year increase, with cadonilimab sales at RMB44.3 million, up 249.5% YoY and 9.6% MoM. Ivonescimab also saw significant growth, with sales of RMB26.6 million, a 517.4% YoY increase. BofAS maintains a Buy rating on Akeso with a target price of HKD162.8.

AASTOCKS News

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

BofAS: Akeso  Cadonilimab Records MoM Growth Against Seasonality

00068

02655

02635

01384

06651

02509

06051

01530

02556

MANYCORE TECH(00068) fell 18.77%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 298.7%. GUOXIA TECH(02655) fell 15.31%, with a trading turnover 444.1 Million HKD, and a year-to-date fell 33%. NUOBIKAN(02635) fell 14.62%, with a trading turnover 148.7 Million HKD, and a year-to-date rose 4.3%.

MANYCORE TECH

GUOXIA TECH

NUOBIKAN

DEEPEXI TECH

51WORLD

QYUNS-B

YOUZAN

3SBIO

MARKETINGFORCE

Top 10 HK Stock Losers (4.23)

01888

01171

06082

09868

01801

KB LAMINATES(01888) rose 10.63%, with a trading turnover 1.8 Billion HKD, and a year-to-date rose 158.8%. WEICHAI POWER(02338) rose 6.76%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 87.6%. AKESO(09926) fell 12.66%, with a trading turnover 3.1 Billion HKD, and a year-to-date rose 15.4%. MINIMAX-W(00100) fell 7.49%, with a trading turnover 1.5 Billion HKD, and a year-to-date rose 420.3%.

- The Hang Seng Index fell by 0.95%, with a year-to-date increase of 1.1%, while the Hang Seng Tech Index decreased by 1.98%, down 11.8% for the year.  
- Jian Tao Jici Ban (01888) rose by 10.63% with a trading volume of 1.76 billion HKD, marking a 158.8% year-to-date increase.  
- Weichai Power (02338) increased by 6.76% with a trading volume of 1.06 billion HKD, showing a 87.6% year-to-date rise, whereas Kangfang Biotech (09926) declined by 12.66%.

KB LAMINATES

YANKUANG ENERGY

BIREN TECH

XPENG-W

INNOVENT BIO

Top 5 HK Stock Gainers/Losers (>100B) (4.23)

Akeso fell 11.52%; Three Senses Pharmaceutical fell 12.73%, with a transaction volume of HKD 1.464 billion; Innovent Biologics fell 5.33%, with a transaction volume of HKD 1.021 billion; Rongchang Biologics fell 7.12%, with a transaction volume of HKD 431 million; BeiGene fell 1.82%, with a market value of HKD 282.4 billion

HK Stock Alerts

Hong Kong stock movement: AKESO fell 11.52%, with increased uncertainty in clinical data and strong market wait-and-see sentiment

AKESO(09926.HK)